Merck, Eisai's combination drug fails in late-stage trial for esophageal cancer
Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...
Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.
Why Is Billionaire Prem Watsa Bullish on Merck & Co., Inc. (MRK) Now?
We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...
Rakuten doses first patients in multi-continental Phase III HNSCC trial
The trial builds off the company’s previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in ...